RSV Seasonal Vaccine Introduction and Growth Strategy
Continuous improvement in R&D productivity
Enabled by advanced technology and partnerships
R&D success rates in phase II have improved to median with phase III and
registration upper quartile, three-year rolling trend
16%
14%
20%
26%
64%
81%
100% 100%
95%
95%
94%
95%
End to end cycle times have improved by 20%
compared to industry median since 2016
helped by vaccines performance
End to end cycle times have decreased by
Areas of focus
3.7 years
Goal to continue to drive portfolio acceleration,
improve R&D success rates, and deliver high value
vaccines and medicines
Doubling-down on data and platform technology,
and in particular using technology to de-risk
targets and progress high-quality first-in-class and
best-in-class opportunities for the right patients
GSK
Phase II
Phase III
Registration
2016-2018
2017-2019
2018-2020 ■2019-2021
•
Increase partnerships for new assets and
capabilities
Source: CMR Clarivate Analytics, 2022. Rolling three year trend 1. Industry median and top quartile values are based on major companies only (those spending ≥US$ 2 billion in 2021 on pharmaceutical R&D)
13View entire presentation